Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Brian abrahams | Rare Historical Photos

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

1

People

Matthew Harrison

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Cantor Fitzgerald

Gilead Sciences

RBC Capital Markets

Vertex Pharmaceuticals

Sarepta Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play